Journal of Oncology Pharmacy Practice

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cremieux, P.
Right arrow Articles by Lefebvre, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cremieux, P.
Right arrow Articles by Lefebvre, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Oncology Pharmacy Practice, Vol. 12, No. 3, 165-178 (2006)
DOI: 10.1177/1078155206069925
© 2006 SAGE Publications

Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application

Pierre Cremieux, PhD

Analysis Group, Inc., Boston, MA, USA, Université du Québec à Montréal, Montreal, Québec, Canada

Francis Vekeman, MA

Groupe d’Analyse, Ltée, Montréal, Québec, Canada

Patrick Lefebvre, MA

Groupe d’Analyse, Ltée, Montréal, Québec, Canada

Objective. To determine the dose-conversion ratio (DCR) between epoetin alfa and darbepoetin alfa in cancer patients and compare the treatment costs of both agents at the estimated DCRs.

Methods. A comprehensive search of the literature was carried out on clinical trials evaluating patients with chemotherapy-related anemia treated with epoetin alfa or darbepoetin alfa. A multivariate meta-analysis regression was conducted to determine the relative doses of these two agents at which they were equally effective. The effectiveness measure used was the area under the hemoglobin change curve. Using the estimated DCR for each dosing regimen, therelativecostofepoetinalfa and darbepoetin alfa treatments in Canada was evaluated.

Results. Twenty-nine study arms, evaluating 12 923 patients (10 582 treated with epoetin alfa and 2341 treated with darbepoetin alfa), were eligible for this study. Results comparing specific dosing regimens indicated that the DCRs were systematically lower than 200:1. The cost premium associated with darbepoetin alfa weekly drug cost was between 37 and 44% above epoetin alfa for the same level of effectiveness.

Conclusion. Based on the evidence from this meta-analysis, epoetin alfa appeared to be more cost-effective compared to darbepoetin alfa in Canada for cancer patients.

Key Words: chemotherapy related anemia • epoetin alfa • darbepoetin alfa • cost effectiveness • dose conversion ratio


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?